A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis.
The currently recommended treatment for individuals exposed to rabies virus is the combined administration of rabies vaccine and rabies immune globulin (RIG). This review sets out the criteria used to guide development of a cocktail of human monoclonal antibodies as a replacement for RIG. Using this process as a model, the general requirements for development of safe and efficacious monoclonal antibody alternatives to currently used polyclonal serum products are discussed.
de Kruif
John
J
Crucell Holland BV, Leiden, The Netherlands. j.dekruif@crucell.com
Bakker
Alexander B H
AB
Marissen
Wilfred E
WE
Kramer
R Arjen
RA
Throsby
Mark
M
Rupprecht
Charles E
CE
Goudsmit
Jaap
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007136:Immunoglobulins / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use*; D011818:Rabies / Q000517:prevention & control*; D011820:Rabies virus / Q000276:immunology
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007136:Immunoglobulins; D007155:Immunologic Factors